Lexaria Awarded Six Additional Patents

(TheNewswire)

• Lexaria now has 60 patents grantedaround much of the world 

• Lexaria urges shareholders to voteat upcoming 2026 Annual Meeting 

Kelowna, British Columbia – January22, 2026 – TheNewswire– Lexaria Bioscience Corp. (Nasdaq: LEXX),(the “Company” or “Lexaria”), a global innovator in drugdelivery platforms is pleased to announce it has reached yet anotherimportant milestone in its strategy of building a strong and diverseintellectual property portfolio: the Company now has a total of 60valid patents granted around most of the major potential marketsaround the world.

Lexaria’s previous update on patents was issuedon October 9,2025. Since then, we have diligentlypursued legal recognition of our innovations leading to intellectualproperty and are delighted to have enjoyed considerable successthrough the receipt of 6 new granted patents.

In our patent Family #20, Compositions and Methods for SublingualDelivery of Nicotine, where we have existinggranted patents in the US, Canada, and Japan, we have received ourfirst patent in Australia.

We have received our first European Union patent inpatent Family #21, Compositions and Methods for Treating Hypertension, where we already have 3 US granted patents. Europe isconsidered the 2nd-largest hypertension market in the world(following the US) and thus receiving European patent recognition isan important milestone.

In our patent Family #24, Compositions and Methods for TreatingEpilepsy, we have received 2 new Australianpatents and 1 new European Union patent. Our intellectual property inthis important Family is now quite robust with a total of 6 USpatents; 4 Australian patents; and 1 European Union patent.

Finally, in our patent Family #27, Compositions and Methods for TreatingDiabetes, we have received 1 new US patent. Wenow have 2 US patents in this Family which we consider to be quiteimportant given our recent successes in the GLP-1 sector.

Lexaria’s exceptional innovations are evidencedthrough its robust patent portfolio. Initial hypotheses are firstevaluated through research of existing scientific papers; followed bythe all-important animal and/or human testing to generate data thatsubsequently supports patent applications in the numerousinternational markets that we have pursued. Only after patents aregranted are we most able to safely pursue commercial relationships toexploit our innovations.

2026 Annual Shareholder MeetingVoting Reminder

The Company would like to remind shareholders to*** VOTE YOUR SHARES*** in Lexaria’s upcoming Annual Meeting whichwill be held on January 27, 2026, at 1:00 PM PT. 

Stockholders holding common stock at the close ofbusiness on December 1, 2025 are entitled to vote at the meeting,even if they have subsequently sold their shares.

Lexaria is asking stockholders to follow theirBoard of Directors’ recommendation to vote FOR all proposals. Regardless of how you vote, we strongly encourage you to vote yourshares on each or on any of the proposals contained in the proxystatement – your opinions matter to us!

How to Access the ProxyMaterials

The proxy statement and annual report to securityholders are available online at: www.colonialstock.com/LEXX2026.
 
On the above website, you can vote by entering your control number;it’s easy! The control number is located on your proxy materials. Ifyou received an email notice, your control number is contained in theemail. If you haven’t received a control number, call your brokerand ask for one.

Lexaria shareholders are encouraged to read the proxy statement andannual report filed in connection with the Meeting in detail and castyour votes prior to the proxy voting deadline (4:00 PM PT on January 26, 2026).

About Lexaria Bioscience Corp. &DehydraTECH

DehydraTECH™ is Lexaria’s patented drug deliveryformulation and processing platform technology which improves the waya wide variety of drugs enter the bloodstream, always through oraldelivery. DehydraTECH has repeatedly evidenced the ability to increasebio-absorption, reduce side-effects, and deliver some drugs moreeffectively across the blood brain barrier. Lexaria operates alicensed in-house research laboratory and holds a robust intellectualproperty portfolio with 60 patents granted and additional patentspending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKINGSTATEMENTS

This press release includes forward-looking statements.Statements as such term is defined under applicable securities laws.These statements may be identified by words such as “anticipate,”“if,” “believe,” “plan,” “estimate,” “expect,”“intend,” “may,” “could,” “should,” “will,” andother similar expressions. Such forward-looking statements in thispress release include, but are not limited to, statements by theCompany relating to the intended use of proceeds from the offering andrelating to the Company’s ability to carry out research initiatives,receive regulatory approvals or grants or experience positive effectsor results from any research or study. Such forward-looking statementsare estimates reflecting the Company’s best judgment based uponcurrent information and involve a number of risks and uncertainties,and there can be no assurance that the Company will actually achievethe plans, intentions, or expectations disclosed in theseforward-looking statements. As such, you should not place unduereliance on these forward-looking statements. Factors which couldcause actual results to differ materially from those estimated by theCompany include, but are not limited to, market and other conditions,government regulation and regulatory approvals, managing andmaintaining growth, the effect of adverse publicity, litigation,competition, scientific discovery, the patent application and approvalprocess, potential adverse effects arising from the testing or use ofproducts utilizing the DehydraTECH technology, the Company’s abilityto maintain existing collaborations and realize the benefits thereof,delays or cancellations of planned R&D that could occur related topandemics or for other reasons, and other factors which may beidentified from time to time in the Company’s public announcementsand periodic filings with the US Securities and Exchange Commission onEDGAR. The Company provides links to third-party websites only as acourtesy to readers and disclaims anyresponsibility for the thoroughness, accuracy or timeliness ofinformation at third-party websites. There is no assurance that any ofLexaria’s postulated uses, benefits, or advantages for the patentedand patent-pending technology will in fact be realized in any manneror in any part. No statement herein has been evaluated by the Food andDrug Administration (FDA). Lexaria-associated products are notintended to diagnose, treat, cure or prevent any disease. Anyforward-looking statements contained in this release speak only as ofthe date hereof, and the Company expressly disclaims any obligation toupdate any forward-looking statements or links to third-party websitescontained herein, whether as a result of any new information, futureevents, changed circumstances or otherwise, except as otherwiserequired by law.

INVESTOR CONTACT:

George Jurcic – Head of InvestorRelations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202

Copyright (c) 2026 TheNewswire - All rights reserved.